Prime Medicine Analyst Ratings
Prime Medicine Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 211.19% | JP Morgan | $27 → $26 | Maintains | Overweight |
| 10/09/2023 | 127.41% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 09/06/2023 | 139.38% | JonesTrading | → $20 | Initiates Coverage On | → Buy |
| 08/14/2023 | 127.41% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 07/31/2023 | 187.25% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
| 04/18/2023 | 115.44% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 01/24/2023 | 151.35% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight |
| 11/14/2022 | 223.16% | JP Morgan | → $27 | Initiates Coverage On | → Overweight |
| 11/14/2022 | 199.22% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/14/2022 | 175.28% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 11/14/2022 | 163.32% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/07/2023 | 211.19% | 摩根大通 | 27 美元 → 26 美元 | 維護 | 超重 |
| 2023 年 9 月 10 日 | 127.41% | BMO Capital | → 19 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 09/06/2023 | 139.38% | JonesTrading | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/14/2023 | 127.41% | 摩根士丹利 | 21 美元 → 19 美元 | 維護 | 重量相等 |
| 07/31/2023 | 187.25% | 古根海姆 | → 24 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/18/2023 | 115.44% | Stifel | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 01/24/2023 | 151.35% | 摩根士丹利 | 23 美元 → 21 美元 | 維護 | 重量相等 |
| 11/14/2022 | 223.16% | 摩根大通 | → 27 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 11/14/2022 | 199.22% | 傑富瑞集團 | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/14/2022 | 175.28% | 摩根士丹利 | → 23 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 11/14/2022 | 163.32% | 高盛 | → 22 美元 | 啓動覆蓋範圍開啓 | → 中立 |
What is the target price for Prime Medicine (PRME)?
Prime Medicine（PRME）的目標價格是多少？
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JP Morgan on November 7, 2023. The analyst firm set a price target for $26.00 expecting PRME to rise to within 12 months (a possible 211.19% upside). 11 analyst firms have reported ratings in the last year.
摩根大通於2023年11月7日公佈了Prime Medicine（納斯達克股票代碼：PRME）的最新目標股價。該分析公司將目標股價定爲26.00美元，預計PRME將在12個月內升至12個月內（可能上漲211.19％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Prime Medicine (PRME)?
分析師對Prime Medicine（PRME）的最新評級是多少？
The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JP Morgan, and Prime Medicine maintained their overweight rating.
摩根大通對Prime Medicine（納斯達克股票代碼：PRME）的最新分析師評級由摩根大通提供，Prime Medicine維持增持評級。
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Prime Medicine（PRME）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表、與Prime Medicine的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Prime Medicine的最新評級是在2023年11月7日發佈的，因此您應該預計下一個評級將在2024年11月7日左右公佈。
Is the Analyst Rating Prime Medicine (PRME) correct?
分析師對 Prime Medicine (PRME) 的評級正確嗎？
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a maintained with a price target of $27.00 to $26.00. The current price Prime Medicine (PRME) is trading at is $8.36, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Prime Medicine（PRME）評級保持不變，目標股價爲27.00美元至26.00美元。Prime Medicine（PRME）目前的交易價格爲8.36美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。